Jefferies Financial Group Inc. Acquires Shares of 7,051 Celcuity, Inc. $CELC

Jefferies Financial Group Inc. acquired a new stake in shares of Celcuity, Inc. (NASDAQ:CELC) during the fourth quarter, Holdings Channel reports. The firm acquired 7,051 shares of the company’s stock, valued at approximately $703,000.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Ogorek Anthony Joseph NY ADV boosted its holdings in Celcuity by 19.7% during the fourth quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company’s stock valued at $66,000 after purchasing an additional 109 shares in the last quarter. US Bancorp DE boosted its holdings in Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after purchasing an additional 143 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Celcuity by 1,329.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after purchasing an additional 319 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Celcuity by 1.2% in the second quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock valued at $570,000 after acquiring an additional 503 shares during the last quarter. Finally, M&T Bank Corp raised its stake in shares of Celcuity by 14.3% in the fourth quarter. M&T Bank Corp now owns 4,671 shares of the company’s stock valued at $465,000 after acquiring an additional 583 shares during the last quarter. 63.33% of the stock is owned by institutional investors and hedge funds.

Celcuity Stock Performance

NASDAQ:CELC opened at $132.88 on Friday. The company has a current ratio of 12.31, a quick ratio of 12.31 and a debt-to-equity ratio of 6.04. The stock has a market capitalization of $6.48 billion, a P/E ratio of -34.07 and a beta of 0.09. The firm has a 50 day moving average of $123.09 and a 200-day moving average of $110.94. Celcuity, Inc. has a 1 year low of $10.50 and a 1 year high of $151.02.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.10. As a group, sell-side analysts anticipate that Celcuity, Inc. will post -3.96 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Citigroup reiterated a “market outperform” rating on shares of Celcuity in a research note on Thursday. Needham & Company LLC reiterated a “buy” rating and issued a $157.00 target price on shares of Celcuity in a research note on Friday, May 15th. Stifel Nicolaus set a $150.00 target price on shares of Celcuity in a research note on Monday, May 4th. HC Wainwright lifted their target price on shares of Celcuity from $165.00 to $185.00 and gave the company a “buy” rating in a research note on Monday, May 18th. Finally, Wall Street Zen cut shares of Celcuity from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Eleven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $150.27.

Insider Buying and Selling

In related news, Director Richard E. Buller sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.46, for a total value of $1,264,140.00. Following the completion of the sale, the director owned 6,760 shares of the company’s stock, valued at $949,509.60. This trade represents a 57.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the completion of the sale, the director directly owned 65,000 shares of the company’s stock, valued at approximately $9,144,200. This represents a 27.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 37,000 shares of company stock valued at $5,111,950. 13.33% of the stock is currently owned by company insiders.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.